Abstract:Introduction and Aims Alzheimer's disease (AD) is characterized by the abnormal accumulation of hyperphosphorylated tau proteins and amyloid-beta (A beta) peptides. Recent studies have shown that many microRNAs (miRNAs) are dysregulated in AD, and modulation of these miRNAs can influence the development of tau and A beta pathology. The brain-specific miRNA miR-128, encoded by MIR128-1 and MIR128-2, is important for brain development and dysregulated in AD. In this study, the role of miR-128 in tau and A beta pathology as well as the regulatory mechanism underlying its dysregulation were investigated.Methods The effect of miR-128 on tau phosphorylation and A beta accumulation was examined in AD cellular models through miR-128 overexpression and inhibition. The therapeutic potential of miR-128 in AD mouse model was assessed by comparing phenotypes of 5XFAD mice administered with miR-128-expressing AAVs with 5XFAD mice administered with control AAVs. Phenotypes examined included behavior, plaque load, and protein expression. The regulatory factor of miR-128 transcription was identified through luciferase reporter assay and validated by siRNA knockdown and ChIP analysis.Results Both gain-of-function and loss-of-function studies in AD cellular models reveal that miR-128 represses tau phosphorylation and A beta secretion. Subsequent investigations show that miR-128 directly inhibits the expression of tau phosphorylation kinase GSK3 beta and A beta modulators APPBP2 and mTOR. Upregulation of miR-128 in the hippocampus of 5XFAD mice ameliorates learning and memory impairments, decreases plaque deposition, and enhances autophagic flux. We further demonstrated that C/EBP alpha transactivates MIR128-1 transcription, while both C/EBP alpha and miR-128 expression are inhibited by A beta.Conclusion Our findings suggest that miR-128 suppresses AD pathogenesis, and could be a promising therapeutic target for AD. We also find a possible mechanism underlying the dysregulation of miR-128 in AD, in which A beta reduces miR-128 expression by inhibiting C/EBP alpha.

Downregulation of miR-132/212 impairs S-nitrosylation balance and induces tau phosphorylation in Alzheimer's disease.

Down‐regulated Expression of Microrna‐338‐5p Contributes to Neuropathology in Alzheimer's Disease

MicroRNA-139 Modulates Alzheimer's-associated Pathogenesis in SAMP8 Mice by Targeting Cannabinoid Receptor Type 2.

MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways

Nitric oxide induces tau hyperphosphorylation via glycogen synthase kinase-3beta activation.

miR‐132 loss de‐represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer's brain

Alzheimer’s Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target

MicroRNA‐128 Suppresses Tau Phosphorylation and Reduces Amyloid‐beta Accumulation by Inhibiting the Expression of GSK3β, APPBP2, and Mtor in Alzheimer's Disease

Downregulation of hsa-miR-132 and hsa-miR-129: non-coding RNA molecular signatures of Alzheimer's disease

miR-132 regulates the expression of synaptic proteins in APP/PS1 transgenic mice through C1q

Mir-124 Downregulates Bace 1 and Alters Autophagy in App/Ps1 Transgenic Mice

NACC2, a molecular effector of miR-132 regulation at the interface between adult neurogenesis and Alzheimer's disease

Downregulation of miR-181c-5p in Alzheimer's disease weakens the response of microglia to Aβ phagocytosis

Loss of miR-369 Promotes Tau Phosphorylation by Targeting the Fyn and Serine/Threonine-Protein Kinase 2 Signaling Pathways in Alzheimer’s Disease Mice

miR-125b promotes tau phosphorylation by targeting the neural cell adhesion molecule in neuropathological progression

Mechanisms of microRNA-132 in central neurodegenerative diseases: A comprehensive review

A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer's Disease

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

miR‐133b as a potential regulator of a synaptic NPTX2 protein in Alzheimer's disease

Identification of potential therapeutic and diagnostic characteristics of Alzheimer disease by targeting the miR-132-3p/FOXO3a-PPM1F axis in APP/PS1 mice

miR-204 silencing reduces mitochondrial autophagy and ROS production in a murine AD model via the TRPML1-activated STAT3 pathway